Zobrazeno 1 - 10
of 145
pro vyhledávání: '"NAOKI TAKEZAKO"'
Autor:
Ryota Urushihara, Naoki Takezako, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kenji Satou, Shinji Nakao, Hiroyuki Takamatsu
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 184-191 (2023)
Abstract The prognostic value of minimal/measurable residual disease (MRD) detection in autografts of patients with multiple myeloma (MM) in an autologous stem‐cell transplantation setting has been reported. Next‐generation flow (NGF) cytometry h
Externí odkaz:
https://doaj.org/article/43040143ccae4cfa9b0a7abca25d1f0a
Autor:
Hideo Wada, Kazuo Kawasugi, Goichi Honda, Noriaki Kawano, Toshimasa Uchiyama, Seiji Madoiwa, Naoki Takezako, Kei Suzuki, Yoshinobu Seki, Takayuki Ikezoe, Toshiaki Iba, Kohji Okamoto
Publikováno v:
TH Open, Vol 07, Iss 01, Pp e65-e75 (2023)
Abstract Background Disseminated intravascular coagulation (DIC) is not a homogeneous condition, but rather includes heterogeneous conditions, and its pathophysiology and outcome vary considerably depending on the background. Although anticoagulant
Externí odkaz:
https://doaj.org/article/0fadba14e37e45bf84126d976b253e62
Autor:
Kazuo Kawasugi, Hideo Wada, Goichi Honda, Noriaki Kawano, Toshimasa Uchiyama, Seiji Madoiwa, Naoki Takezako, Kei Suzuki, Yoshinobu Seki, Takayuki Ikezoe, Toshiaki Iba, Kohji Okamoto
Publikováno v:
Thrombosis Journal, Vol 19, Iss 1, Pp 1-7 (2021)
Abstract Background In patients with infectious diseases, disseminated intravascular coagulation (DIC) is often diagnosed without the fibrinogen value. The relationship between hypofibrinogenemia and outcomes of DIC in infectious diseases has thus re
Externí odkaz:
https://doaj.org/article/e3b3c1e6e832443b972da6714f07c7af
Autor:
Noriaki Kawano, Hideo Wada, Toshimasa Uchiyama, Kazuo Kawasugi, Seiji Madoiwa, Naoki Takezako, Kei Suzuki, Yoshinobu Seki, Takayuki Ikezoe, Tsuyoshi Hattori, Kohji Okamoto
Publikováno v:
Thrombosis Journal, Vol 18, Iss 1, Pp 1-9 (2020)
Abstract Background Although disseminated intravascular coagulation (DIC) is life-threatening, any organ failure associated with DIC resolution and outcomes have been unclear. Patients and methods A total of 2795 DIC patients (infection: 1990, hemato
Externí odkaz:
https://doaj.org/article/02a339db6fd44479872af8f74b278a99
Autor:
Seki Yoshinobu MD, PhD, Goichi Honda PhD, Noriaki Kawano MD, PhD, Toshimasa Uchiyama MD, PhD, Kazuo Kawasugi MD, PhD, Seiji Madoiwa MD, PhD, Naoki Takezako MD, PhD, Ikezoe Takayuki MD, PhD, Hideo Wada MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
The aims of this study were to analyze the clinical features of a large number of cases with disseminated intravascular coagulation (DIC) associated with acute leukemia and to assess the safety and efficacy of thrombomodulin alfa (TM-α) using the Fr
Externí odkaz:
https://doaj.org/article/3506b2808fc24351a43a03d925724d94
Autor:
Hideo Wada MD, PhD, Goichi Honda PhD, Noriaki Kawano MD, PhD, Toshimasa Uchiyama MD, PhD, Kazuo Kawasugi MD, PhD, Seiji Madoiwa MD, PhD, Naoki Takezako MD, PhD, Kei Suzuki MD, PhD, Yoshinobu Seki MD, PhD, Takayuki Ikezoe MD, PhD, Toshiaki Iba MD, PhD, Kohji Okamoto MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
The frequency of severe antithrombin deficiency (SAD) was examined in the hematopoietic disorder-, infectious-, and basic-types of the disseminated intravascular coagulation (DIC). A posthoc analysis of 3008 DIC patients (infectious-type, 1794; hemat
Externí odkaz:
https://doaj.org/article/b343d7c838614d539efb7cff704b0374
Autor:
Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet-Loiseau, Saad Z. Usmani
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include
Externí odkaz:
https://doaj.org/article/34bc86c721f547c0b175882c23aa9838
Autor:
KAZUHITO SUZUKI, MORIO MATSUMOTO, YASUSHI HIRAMATSU, NAOKI TAKEZAKO, YOTARO TAMAI, KENSHI SUZUKI
Publikováno v:
Cancer Diagnosis & Prognosis; Mar/Apr2024, Vol. 4 Issue 2, p97-104, 8p
Autor:
Kazuhito Suzuki, Morio Matsumoto, Yasushi Hiramatsu, Naoki Takezako, Yotaro Tamai, Kenshi Suzuki
Publikováno v:
Acta haematologica.
Introduction: Elotuzumab and lenalidomide plus dexamethasone (ERd) is a standard salvage chemotherapy for multiple myeloma, and elotuzumab is commonly administered every 2 weeks after cycle 3 (conventional ERd). Alternatively, elotuzumab may often be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::481ee4f6f1bce0028a32572b4e8c19f6
https://pubmed.ncbi.nlm.nih.gov/36538896
https://pubmed.ncbi.nlm.nih.gov/36538896
Autor:
Meletios A. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, David Yao, Prianka Das, Jesús San-Miguel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
PURPOSE In the phase II ELOQUENT-3 trial (ClinicalTrials.gov identifier: NCT02654132 ), elotuzumab combined with pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) versus pomalidomide/dexamethasone (Pd) in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e288b2851c6e74f2ff97875cf62ed97
https://pubmed.ncbi.nlm.nih.gov/35960908
https://pubmed.ncbi.nlm.nih.gov/35960908